These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 10818719)
21. Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers. Talmadge JE; Oldham RK; Fidler IJ J Biol Response Mod; 1984; 3(1):88-109. PubMed ID: 6707701 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells. Stewart TJ; Smyth MJ; Fernando GJ; Frazer IH; Leggatt GR Cancer Res; 2003 Jun; 63(12):3058-60. PubMed ID: 12810627 [TBL] [Abstract][Full Text] [Related]
23. NK cell receptors as tools in cancer immunotherapy. Sentman CL; Barber MA; Barber A; Zhang T Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660 [TBL] [Abstract][Full Text] [Related]
24. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity. Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876 [TBL] [Abstract][Full Text] [Related]
25. Prospects for the use of NK cells in immunotherapy of human cancer. Ljunggren HG; Malmberg KJ Nat Rev Immunol; 2007 May; 7(5):329-39. PubMed ID: 17438573 [TBL] [Abstract][Full Text] [Related]
26. First-in-class cancer therapeutic to stimulate natural killer cells. Sheridan C Nat Biotechnol; 2006 Jun; 24(6):597. PubMed ID: 16763573 [No Abstract] [Full Text] [Related]
27. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies. Fujii S Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215 [TBL] [Abstract][Full Text] [Related]
28. IL-15: targeting CD8+ T cells for immunotherapy. Diab A; Cohen AD; Alpdogan O; Perales MA Cytotherapy; 2005; 7(1):23-35. PubMed ID: 16040381 [TBL] [Abstract][Full Text] [Related]
29. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model. Hess SD; Egilmez NK; Shiroko J; Bankert RB Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457 [TBL] [Abstract][Full Text] [Related]
30. Effects of ex vivo activated immune cells on syngeneic and semi-allogeneic bone marrow transplantation in mice. Yang G; Tan J; Wei G; Deng Y; Chen H; Yang D Transpl Immunol; 2006 Nov; 16(3-4):166-71. PubMed ID: 17138049 [TBL] [Abstract][Full Text] [Related]
31. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Li J; Hu P; Khawli LA; Epstein AL Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000 [TBL] [Abstract][Full Text] [Related]
32. When killers become helpers. Hanna J; Mandelboim O Trends Immunol; 2007 May; 28(5):201-6. PubMed ID: 17403615 [TBL] [Abstract][Full Text] [Related]
33. Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2. Lee KD; Chen HW; Chen CC; Shih YC; Liu HK; Cheng ML Oncol Rep; 2006 May; 15(5):1211-6. PubMed ID: 16596189 [TBL] [Abstract][Full Text] [Related]